How does ICPT *'s PS Ratio compare to its peers?

ICPT * is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (26.1x).

How does ICPT *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

ICPT * is good value based on its Price-To-Sales Ratio (1.7x) compared to the Global Biotechs industry average (9.6x).

What is ICPT *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ICPT *'s Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of ICPT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ICPT * (MX$329) is trading below our estimate of [[fair value]] (MX$519.51)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Intercept Pharmaceuticals (BMV:ICPT *) - Stock Price, News & Analysis

ICPT * Stock Overview

ICPT * fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 36.7% below our estimate of its fair value

Earnings are forecast to grow 63.85% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Intercept Pharmaceuticals, Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.7b

Yantai Zhenghai Biotechnology

SZSE:300653

CN¥3.8b

CK Life Sciences Int'l. (Holdings)

SEHK:775

HK$4.3b

Ironwood Pharmaceuticals

NasdaqGS:IRWD

US$534.5m

Price History & Performance

Summary of all time highs, changes and price drops for Intercept Pharmaceuticals
Historical stock prices
Current Share Price	US$329.00
52 Week High	US$0
52 Week Low	US$0
Beta	1.27
11 Month Change	0%
3 Month Change	0%
1 Year Change	0%
33 Year Change	-83.98%
5 Year Change	n/a
Change since IPO	-78.86%

Recent updates

Shareholder Returns

	ICPT *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	0%	0%	0%

Return vs Industry: ICPT * exceeded the MX Biotechs industry which returned -6% over the past year.

Return vs Market: ICPT * underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is ICPT *'s price volatile compared to industry and market?
ICPT * volatility
ICPT * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ICPT * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ICPT *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.

Intercept Pharmaceuticals, Inc. Fundamentals Summary

How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap?
ICPT * fundamental statistics
Market cap	Mex$8.54b
Earnings (TTM)	-Mex$3.00b
Revenue (TTM)	Mex$5.09b

1.7x

P/S Ratio

-2.9x

P/E Ratio

Is ICPT * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICPT * income statement (TTM)
Revenue	US$294.52m
Cost of Revenue	US$983.00k
Gross Profit	US$293.54m
Other Expenses	US$466.84m
Earnings	-US$173.30m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.16
Gross Margin	99.67%
Net Profit Margin	-58.84%
Debt/Equity Ratio	495.7%

How did ICPT * perform over the long term?

See historical performance and comparison

ICPT * Stock Overview

Rewards

Risk Analysis

Intercept Pharmaceuticals, Inc. Competitors

BMV:LAB B

Mex$24.7b

SZSE:300653

CN¥3.8b

SEHK:775

HK$4.3b

NasdaqGS:IRWD

US$534.5m

Price History & Performance

Recent News & Updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Shareholder Returns

Price Volatility

About the Company

Intercept Pharmaceuticals, Inc. Fundamentals Summary

1.7x

-2.9x

Earnings & Revenue